Rochester, NY – (30 Nov 2016) Koning Corporation was showcased at the scientific assembly of the Radiological Society of North America (RSNA). Held annually in Chicago, IL, RSNA draws over fifty thousand members, medical professionals, and leading medical technology manufacturers. Among hundreds of participants presenting variety of mammograms and other breast cancer screening and diagnostic devices, Koning’s Breast CT (KBCT) device was the only FDA-approved breast CT imaging system to be showcased. A unique modality, the KBCT provides 3D isotropic multi-planar images of the breast – without compression and with high dose efficiency. This technology allows for precise detection, assessment, and quantification of abnormalities, including in women with dense breast tissue.
Hundreds of medical professionals turned up to see the device in person, accentuating the fact that Koning is leading the revolution in breast cancer imaging and diagnostics. Following its receipt of the FDA approval, Koning has been awarded numerous awards. In August, Koning announced the receipt of the Frost and Sullivan 2016 North American Breast Imaging New Product Innovation Award. Koning Breast CT (KBCT) was selected from a large pool of outstanding medical device manufacturers and other industry leaders. The Best Practices Awards are presented each year to companies that are predicted to encourage significant growth in their industries, have identified emerging trends before they became the standard in the marketplace, and have created advanced technologies that will catalyze and transform industries in the near future. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research in order to identify potential nominees and subsequent awardees. In conjunction with industry analysts, Frost & Sullivan recognized Koning’s technology as one of the most significant innovations in the breast imaging space over the last few years. According to Frost and Sullivan, the KBCT is an extremely valuable new addition to the gamut of breast imaging modalities. In a statement issued by the firm, Frost and Sullivan states that in recognition of the tremendous innovation underlying the KBCT, Koning Corporation is the deserving recipient of the 2016 Frost & Sullivan New Product Innovation Award.
Separately, Koning Corporation was honored by another prestigious international organization by receiving a nomination for the Galien Foundation’s Prix Galien award in the Best Medical Technology category for its Koning Breast CT (KBCT) devise. The Prix Galien, regarded worldwide as the equivalent of the “Nobel Prize in biopharmaceutical and medical technology research,” is an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. To qualify, each candidate must be U.S. Food and Drug Administration (FDA) approved for market within the last five years and demonstrate tremendous potential to impact human health. Although Koning ultimately did not win the award, it was the smallest company in terms of its market capitalization to be nominated.
About Koning Corporation
Founded in 2002, Koning Corporation has become the innovator in breast imaging and breast cancer diagnostics. Koning Corporation’s KBCT received the Food and Drug Administration (FDA) approval in January 2015, making it the first dedicated breast CT imaging system to launch in the North American marketplace. Koning Corporation also received China FDA approval in November, 2015. This follows KBCT’s Conformité Européenne (CE) mark for the European Union, which it obtained in 2012, in addition to a series of other regulatory approvals including for the Australian and Canadian markets. As it continues to execute its global expansion, the company is currently in the process of obtaining regulatory approvals for countries in the Asia-Pacific and South America regions, notably in Japan, Singapore, Malaysia, the Philippines, Brazil, Mexico, and others.
The Radiological Society of North America (RSNA) is an international society of radiologists, medical physicists and other medical professionals with more than 54,000 members from 136 countries across the globe. RSNA hosts the world’s premier radiology forum, drawing approximately 55,000 attendees annually to McCormick Place in Chicago, and publishes two top peer-reviewed journals: Radiology, the highest-impact scientific journal in the field, and RadioGraphics, the only journal dedicated to continuing education in radiology.
Through its educational resources, RSNA provides hundreds of thousands of continuing education credits toward physicians’ maintenance of certification—more than one million CME certificates have been awarded since 2000. The Society also develops and offers informatics-based software solutions in support of a universal electronic health record, sponsors research to advance quantitative imaging biomarkers, and conducts outreach to enhance education in developing nations. Through its Research & Education (R&E) Foundation, RSNA provides millions of dollars in funding to young investigators, helping to build the future of the profession.